{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:57:14Z","timestamp":1784973434547,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"publisher","award":["TKP2021-EGA-18"],"award-info":[{"award-number":["TKP2021-EGA-18"]}],"id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejps.2025.107119","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T02:48:28Z","timestamp":1746499708000},"page":"107119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sex differences in suspected adverse drug reactions of anti-seizure medications reported in EudraVigilance"],"prefix":"10.1016","volume":"210","author":[{"given":"Michael Magdy Fahmy","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Farkasinszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Vecserny\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"B\u00e1cskay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-7052","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107119_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int. Rev. Neurobiol."},{"issue":"12","key":"10.1016\/j.ejps.2025.107119_bib0002","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/epi.13210","article-title":"Availability of antiepileptic drugs across Europe","volume":"56","author":"Baftiu","year":"2015","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ejps.2025.107119_bib0003","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-019-02678-1","article-title":"Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation","volume":"75","author":"Baftiu","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2025.107119_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNF.0b013e31829a498d","article-title":"Adverse effects of antiepileptic drugs in North Indian pediatric outpatients","volume":"36","author":"Bansal","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2025.107119_bib0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.ejps.2025.107119_bib0006","doi-asserted-by":"crossref","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107119_bib0008","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/20.176","article-title":"Insurance barriers, gendering, and access: interviews with Central North Carolinian women about their health care experiences","volume":"25","author":"Cardoso","year":"2021","journal-title":"Perm J."},{"key":"10.1016\/j.ejps.2025.107119_bib0009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yebeh.2014.09.051","article-title":"Sex differences in seizure types and symptoms","volume":"41","author":"Carlson","year":"2014","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.ejps.2025.107119_bib0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/epi4.12632","article-title":"Differences between men and women in response to antiseizure medication use and the likelihood of developing treatment resistant epilepsy","volume":"7","author":"Cepeda","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ejps.2025.107119_bib0011","series-title":"Summary of Product Characteristics","year":"2013"},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0012","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Disease Prim."},{"key":"10.1016\/j.ejps.2025.107119_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106547","article-title":"Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy","volume":"170","author":"Gesche","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2025.107119_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1411134","article-title":"Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications: a pharmacovigilance study using EudraVigilance database","volume":"15","author":"Girgis","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107119_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.643450","article-title":"Gender and socioeconomic disparities in global burden of epilepsy: an analysis of time trends from 1990 to 2017","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejps.2025.107119_bib0016","first-page":"1","article-title":"Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System","author":"Huang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejps.2025.107119_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106885","article-title":"Seizure exacerbation with anti-seizure medications in adult patients with epilepsy","volume":"181","author":"Jaramillo","year":"2022","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2025.107119_bib0018","series-title":"Post-reform personal data protection in the European Union","author":"Krzysztofek","year":"2017"},{"issue":"4","key":"10.1016\/j.ejps.2025.107119_bib0019","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3181cbcd5c","article-title":"Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients","volume":"74","author":"Mattsson","year":"2010","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ejps.2025.107119_bib0020","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2022030323","article-title":"Sex differences in age-related loss of kidney function","volume":"33","author":"Melsom","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107119_bib0021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nrl.2018.01.011","article-title":"Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations","volume":"35","author":"Mercad\u00e9 Cerd\u00e1","year":"2020","journal-title":"Neurol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0022","article-title":"Anticonvulsant prescription patterns in patients covered by the Colombian Health System","volume":"32","author":"Morales-Plaza","year":"2017","journal-title":"Neurologia"},{"issue":"2","key":"10.1016\/j.ejps.2025.107119_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WNF.0b013e318210ece0","article-title":"Adverse reactions to antiepileptic drugs in epileptic outpatients: a cross-sectional study in iran","volume":"34","author":"Namazi","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejps.2025.107119_bib0024","unstructured":"Note for guidance \u2013 EudraVigilance Human \u2013 Processing of safety messages and individual case safety reports (ICSRs): European Medicines Agency; 2010 [15 October 2010 EMA\/H\/20665\/04\/Final Rev. 2 EudraVigilance Expert Working Group]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/note-guidance-eudravigilance-human-processing-safety-messages-individual-case-safety-reports-icsrs_en.pdf."},{"key":"10.1016\/j.ejps.2025.107119_bib0025","series-title":"Regulation 2018\/1725 on the protection of natural persons with regard to the processing of personal data by the EU institutions, bodies, offices and agencies","year":"2019"},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0026","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12978-021-01151-6","article-title":"The influence of social and cultural practices on maternal mortality: a qualitative study from South Punjab, Pakistan","volume":"18","author":"Omer","year":"2021","journal-title":"Reproductive Health."},{"issue":"Pt B","key":"10.1016\/j.ejps.2025.107119_bib0027","article-title":"Gender issues in antiepileptic drug treatment","volume":"72","author":"Perucca","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"37","key":"10.1016\/j.ejps.2025.107119_bib0028","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170926103631","article-title":"Specific patient features affect antiepileptic drug therapy decisions: focus on gender, age, and psychiatric comorbidities","volume":"23","author":"Pisani","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2025.107119_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.49.1.47","article-title":"Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy","volume":"49","author":"Ro\u015bciszewska","year":"1986","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"8","key":"10.1016\/j.ejps.2025.107119_bib0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2025.107119_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956825","article-title":"Capillary leak syndrome following COVID-19 vaccination: data from the European pharmacovigilance database Eudravigilance","volume":"13","author":"Ruggiero","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107119_bib0033","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-019-1271-3","article-title":"The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas","volume":"17","author":"Stangl","year":"2019","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0034","article-title":"Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database","volume":"19","author":"Tomson","year":"2010","journal-title":"Epilepsy Behav. E&B"},{"issue":"2","key":"10.1016\/j.ejps.2025.107119_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2010.02897.x","article-title":"Antiepileptic drugs, sex hormones, and PCOS","volume":"52","author":"Verrotti","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2025.107119_bib0036","article-title":"A systematic review of the risks factors associated with the onset and natural progression of epilepsy","volume":"61","author":"Walsh","year":"2017","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejps.2025.107119_bib0037","unstructured":"WHOCC. WHOCC - ATC\/DDD Index 2016 [Available from: http:\/\/www.whocc.no\/atc_ddd_index\/."},{"issue":"2","key":"10.1016\/j.ejps.2025.107119_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlpt.2021.100522","article-title":"The willingness and its influencing factors on patients to participate in patient safety spontaneous reports: a cross-sectional online study in China","volume":"10","author":"Xiang","year":"2021","journal-title":"Health Policy Technol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107119_bib0039","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:21:56Z","timestamp":1762330916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"alternative-id":["S0928098725001186"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107119","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in suspected adverse drug reactions of anti-seizure medications reported in EudraVigilance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107119"}}